Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

Foundations 2 > Drugs > Flashcards

Drugs Flashcards

1
Q

Warfarin

Therapeutic Use, Mechanism of Action, Side Effects, Therapeutic Index, Metabolism, Pharmacogenomics, TDM

A

Therapeutic Use: Increases clotting time (anticoagulant) to prevent thrombi/stroke
Mechanism of Action: suppresses VKORC1 - reduces vitamin K regeneration - blocks carboxylation of coagulation factors
Side Effect: Increases bleeding if dose is too high
TI: ~1 - very narrow sweet spot
Metabolism: CYP2C9
Pharmacogenomics: CYP2C92/3 have reduced function - poor metabolizers need more days to determine if anticoagulation is stable & TDM via INR (international normalized ratio of patient prothrombin time - how long it takes to clot - adjust dose based on this number)
Pharmacodynamics: VKORC1 haplotype A - more sensitive to drug than wild-type G - higher risk of hemorrhagic activity
Dosage scheme depends on genetics of CYP2C9 and VKORC1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Benzodiazepines [-azepam + -azolam]
Diazepam [Valium]
Midazolam [Versed]

(Therapeutic Use, Mechanism of Action, Side Effect, TI, Metabolism)

A

Therapeutic Use: sedation, improve sleep, treat anxiety + muscle spasms
Mechanism of Action: allosteric activator of GABA-a receptors (binds b/w b+g subunits) - increase IPSP, increase Cl- current by increasing frequency of channel openings
Side Effect: over-sedation, dizziness, confusion, memory loss
TI: ~100+ (safer)
Metabolism: CYP3A4 hydroxylation [CYP2C19 helps with -azepams] (reduce 90% activity) & Glucuronidation (very water soluble and inactive form)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Sulfonylureas

Mechanism of Action

A

inhibit K-ATP channels, resulting in depolarized Vrest, allowing V-gated Ca channels to open and cause insulin secretion in pancreas and vasoconstriction in SMC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Minoxidil

Therapeutic Use, Mechanism of Action

A

Therapeutic Use: Treat HT
Mechanism of action: activates K-ATP receptors in SMC - hyperpolarized Vrest - v-gated Ca channels harder to open - more vasodilatation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q 
Local Anaesthetics 
(Therapeutic Use, Mechanism of Action, and Special Characteristic)
A

Therapeutic Use: Localized pain reduction
Mechanism of Action: Block V-gated Na Channels by enhancing inactivation (preferential binding to inactivated state);
Use-Dependent Block: inhibition intensifies with use as more Na channels get inactivated after every AP (good for neurons that fire frequently - pain nerves + epilepsy); weak base than enters channel from cytosolic side through fenestrations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Tetrodotoxin (TTX)

Therapeutic Use, Mechanism of Action

A

Use: Eating pufferfish, should be just enough to make your fingertips tingle, POISON
Mechanism of Action: Potent Na Channel Blocker; acts like plug on EC side of channel (Pre-synaptic Transmission NMJ), also EC block on nicotinic receptor (Post-synaptic Transmission NMJ)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Drug Class: L-Type Ca++ Channel Blockers (Mechanism of Action, Therapeutic Uses)

A

Mechanism of Action: shorten cardiac AP plateau (phase II) = shorten AP
Use: treat angina, HT (inhibit SMC VC), Arrythmia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Drug Class: Na+ Channel Blockers (Mechanism of Action, Therapeutic Uses)

A

Mechanism of Action: Decrease/Attenuate depolarization upstroke (blunts rate of rise) - slows AP conduction through heart - prevents re-entry loops
Therapeutic Uses: local anaesthesia, arrhythmia, epilepsy/migraines

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Drug Class: K+ Channel Blockers

Mechanism of Action, Therapeutic Uses, Side Effect

A

Mechanism of Action: impair repolarization in phase III - longer cardiac AP
Therapeutic Uses: arrhythmia
Side Effect: Drug Induced LQTS, pro-arrhythmic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Ondansetron (Zofran) and -setrons

Mechanism of Action, Therapeutic Use

A

Mechanism of Action: Competitive Antagonist at 5-HT3 Serotonin Receptors
Therapeutic Uses: Treat nausea + vomiting (that typically occurs because of cancer chemotherapy agents)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Zolpidem (Ambien)

Mechanism of Action, Therapeutic Use, Key Feature

A

Mechanism of Action: binds selectively to specific B[a]p sites involved in producing sleep
Therapeutic Use: help fall asleep
Allosteric Activator - reduces likelihood of receptor desensitization

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Penicillin

Side Effect, Mechanism of Action, Excretion

A

Major Side Effect: blocks open GABA-a receptor channels - induces seizures!
Mechanism of Action: uncompetitive antagonist to activated GABA-a channels - CONVULSANT
Excretion: Tubular Secretion (through OATs, competing pathway with Probenecid causes prolonged penicillin activity - GOOD)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Strychnine

Mechanism of Action, Effect

A

Mechanism of Action: Post-synaptic inhibitor, competitive inhibitor of glycine receptors
Effect: causes excessive spasticity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q 
Tetanus Toxin 
(Mechanism of Action, Effect)
A

Mechanism of Action: Pre-synaptic inhibitor, blocks glycine release
Effect: causes excessive spasticity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Memanite

Mechanism of Action, Effect

A

Mechanism of Action: binds to open NMDA channel (uncompetitive antagonist) and inhibits Ca2+ flow
Effect: May be used to treat Alzheimer’s and seizures
Acts like penicillin (uncompetitive antagonist)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Fluticasone [-son- and -one drugs]

Mechanism of Action, Effect

A

Mechanism of Action: activates glucocorticoid receptors to inhibit inflammatory response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Selective Serotonin Reuptake Inhibitors [SSRIs]

Mechanism of Action, Therapeutic Use

A

Mechanism of Action: blocks SLC6A4 serotonin reuptake SLC secondary active transporter
Therapeutic Use: anti-depressent (more serotonin lingering in synaptic cleft)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Grapefruit Juice [Furanocoumarins]

Mechanism of Action, Effect, Low vs. High F, Oral vs. IV

A

Mechanism of Action: Inhibit CYP3A4 + PGP, increasing bioavailability of drugs
Effect: Toxic elevations of drug in systemic circulation
Large effects on drugs with low F - bigger boosts possible
Only affects orally ingested drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Cimetidine [-idine]

Mechanism of Action, Key Feature, Metabolism Reaction, Problem

A

Mechanism of Action: Competitive Inhibitor (complementary shape) for H2 Histamine Receptor
Metabolized by S-oxidation
Inhibits many types of CYPs cause of drug:drug interaction toxic buildup
Desensitization: continual use causes GCPR receptor upregulation, over-inhibition suppresses internalization/degradation

20
Q

Caffeine

Use, Mechanism of Action, Metabolism Reaction, Family

A

Use: stimulant
Mechanism of Action: competitive inhibitor (complementary shape to adenosine) of adenosine receptor at low doses (disinhibition of cellular functions)
Minor Mechanism: inhibits phosphodiesterases at higher doses (increase cAMP and signaling through pathway)
Metabolism: N-dealkylation to active metabolite or theophylline
METHYLXANTHINE FAMILY WITH THEOPHYLLINE

21
Q

Theophylline

Use, Mechanism of Action, Metabolism Reaction, Family

A

Use: last resort to treat bronchiole disorders
Mechanism of Action: competitive inhibitor (complementary shape to adenosine) of adenosine receptor at low doses (disinhibition of cellular functions)
Minor Mechanism: inhibits phosphodiesterases at higher doses (increase cAMP and signaling through pathway)
Metabolism: N-dealkylation to inactive metabolite
METHYLXANTHINE FAMILY WITH CAFFEINE

22
Q

Ethanol

Pathway, Problem

A

Pathway: EtOH - alcohol dehydrogenase oxidizes to - acetaldehyde (TOXIC drunk guy) - aldehyde dehydrogenase oxidizes to - acetate
Problem: Role in Acetaminophen toxicity - high ethanol induces CYP2E1, which can metabolize acetaminophen into toxic NAPQI
Polymorphisms: “Asian Glow” Chinese more likely to have enhanced alcohol DH and reduced aldehyde DH = toxic buildup of aldehyde causes facial flushing

23
Q

Succinylcholine

Mechanism of Action, Metabolism

A

Mechanism of Action: prevents ACh excitation of skeletal muscle; depolarizing blocker - fastest known ACh blocker b/c you can overload dose and it’ll be degraded
Metabolism: Degraded twice via ester hydrolysis by pseudocholinesterases

24
Q

Acetaminophen

Therapeutic Use, Mechanism of Action, Metabolism, Treatment for Metabolism Problems

A

Therapeutic Use: analgesic & antipyretic
Mechanism of Action: inhibits cyclooxygenases (housekeeping COX1 + painful COX2)
Metabolism: no phase I reaction because already hydroxylated, many possible pathways:
A. Sulfation to nontoxic inactivated form (LOW DOSES)
B. Glucuronidation to nontoxic inactivated form (LOW DOSES)
C. HIGH DOSES: CYP2E1 + CYP3A4 make NAPQI (reactive toxic intermediate electrophile kills hepatocytes) - metabolized again via GLUTATHIONE GSTs - requires glutathione
*If HIGH DOSE AND LOW GLUTATHIONE - NAPQI reacts with nucleophilic macromoleculs, triggering liver cell death
Treatment: N-acetylcysteine - complementary shape to glutathione, but less polar so it can diffuse through lipid bilayer (anti-inflammatory and antioxidant)

25
Albuterol | Therapeutic Use, Mechanism of Action
Therapeutic Use: rescue inhaler for asthma, treats COPD | Mechanism of action: beta-2 receptor agonist (relax SMC)
26
Codeine | Therapeutic Use, Metabolism, Key Feature, Pharmacogenomics
Therapeutic Use: Pro-drug analgesic Metabolism: via O-dealkylation by CYP2D6 (Phase I) to Morphine (activated Drug) Key Feature: Morphine involved in Enterohepatic Cycle (Antibiotics cause increased half-life) Pharmacogenomics: Affects Biotransformation, CYP2D6 polymorphisms create poor metabolizers (ineffective doses) and ultra-rapid metabolizers (toxicity)
27
Hydrocodone | Therapeutic Use, Metabolism
Therapeutic Use: active analgesic, also a pro-drug to become even more active Metabolism: via O-dealkylation by CYP2D6 (Phase I) to Hydrophorphone (even more activated) (poor metabolizers need more and rapid metabolizers need less)
28
Metoprolol | Therapeutic Use, Mechanism of Action, Metabolism
Therapeutic Use: anti-HT, anti-anginal, antiarrhythmic (like propanolol but MORE selective) Mechanism of Action: Selectively blocks beta-1 receptors (inhibiting causes decrease in HR and contractility) - good beta blockers for asthmatics b/c doesn't block airway Metabolism: CYP2D6 inactivates (poor metabolizers need less and rapid metabolizers need more)
29
Omeprazole (-prazoles) | Therapeutic Use, Mechanism of Action, Metabolism
PROTON PUMP INHIBITOR Therapeutic Use: treat excess acid secretion disorders (ulcers) Mechanism of Action: irreversibly blocks proton pump + prevents acid secretion Metabolism: CYP2C19
30
Clopidogrel [Plavix] | Therapeutic Use, Metabolism, Pharmacogenomics - KNOW THE VARIANTS
Therapeutic Use: Anti-platelet Activity Metabolism: Pro-drug activated by twice metabolism through CYP2C19 Pharmacogenomics: CYP2C19*2/*3 variants cause reduced function, impaired anti-platelet effects - high risk of thrombosis/stroke - even in carriers with one of these variants!
31
Ibuprofen | Family, Therapeutic Use, Mechanism of Action, Metabolism
NSAIDs - non-steroidal anti-inflammatory drugs Therapeutic Use: pain-reliever + anti-inflammatory Mechanism of Action: inhibits both housekeeping COX1 and painful COX2 enzymes Metabolism: CYP2C9 - polymorphic poor metabolizers have reduced clearance
32
Celecoxib | Family, Therapeutic Use, Mechanism of Action, Metabolism
NSAIDs - non-steroidal anti-inflammatory drugs Therapeutic Use: pain-reliver + anti-inflammatory - used more than Ibuprofen in treating post-operative pain Mechanism of Action: Selectively inhibits painful COX2 Metabolism: CYP2C9 - polymorphic poor metabolizers have reduced clearance
33
Imatinib [Gleevec] | Mechanism of Action, Therapeutic Use
Mechanism of Action: binds to ATP-binding site of constitutively active BCR-ABL Tyrosine Kinase to prevent ATP binding and phosphorylation Therapeutic Use: Treat specific type of CML
34
Digoxin | What is it, Complications
Cardiac Medication Transport: Uses OCT on basolateral side in Tubular Secretion Competes with: Quinidine (another cardiac medication) - Prolonged half-lives, toxic build-up Key Drug in Enterohepatic Cycle (Antibiotics kill gut bacteria - decrease drug's half life)
35
Estradiol | What is it, Complications
Birth Control | Key Drug in Enterohepatic Cycle (Antibiotics kill gut bacteria - decrease drug's half life - cause unplanned pregancies)
36
Statins | Mechanism of Action, Complications
Mechanism of Action: Inhibit HMG CoA Reductase - prevent cholesterol biosynthesis - treat familial hypercholesterolemia Transport: Biliary Drug Excretion through SLC01B1 (OATP1B1)* polymorphisms cause increased sensitivity and toxicity - myotoxicity + muscle injury
37
Tacrolimus | Therapeutic Use, TI, F, Metabolism, Pharmacogenomics
Therapeutic Use: Immunosuppressant, prevents organ rejection in transplants, treats inflammatory/autoimmune disorders TI: NARROW requires TDM F: Low F due to high first pass metabolism Metabolism: by CYP3A4 (no polymorphisms) + CYP3A5 (polymorphisms significant!) Pharmacogenomics: CYP3A5 variants have 1nc change in splice site that makes enzyme NON-functional - extremely common in Caucasians Poor Metabolizers: Non-functional diplotype - most prevalent in Caucasians - considered norm - use standard dose and monitor with TDM Intermediate/Extensive Metabolizers: increase starting dose
38
Thiopurines | Therapeutic Use, Pharmacogenomics
Therapeutic Use: Pro-Drugs require conversion to THIOGUANINES for anti-cancer cytotoxicity Pathway: Thiopurine - 6-MP - Thioguanine TPMT: Enzyme that converts intermediate 6-MP into inactive form Pharmacogenomics: variants have impaired TPMT function Poor metabolizers: less elimination - increased risk for bone marrow suppression - need to give lower doses for variant carriers
39
Mg2+ and other polyvalent cations (Mn, Co, La) | Mechanism of Action
Block pre-synaptic Calcium ion entry into nerve terminal at NMJ
40
Botulinum Toxin Type A | Mechanism of Action, Therapeutic Use
1. cleaves SNAP-25 in fusion machinery - inhibits priming of secretion and release of ACh at NMJ 2. Therapeutic Use: Treats blepharospasm
41
-curoniums | Mechanism of Action
1. Most popular non-depolarizing competitive inhibitors of nicotinic ACh receptors at NMJ
42
Neostigmine [-stigmines] | Mechanism of Action, Therapeutic Use
1. reversible inhibitor of AChE at NMJ - prolongs effects of ACh 2. speeds recovery from -curoniums after surgery, treats Myasthenic Gravus
43
Atropine | Mechanism of Action, Therapeutic Use
1. competitive inhibitor of ACh at mAChR's in heart (parasympathetic), blocks vagal slowing 2. Increases HR during spinal anesthesia
44
Ipratropium, Tiotropium [-tropiums] | Mechanism of Action, Therapeutic Use
1. competitive inhibitor of ACh at mAChR's in bronchioles (parasympathetic), reduces constriction to open airway 2. Treat airway disorders (Asthma, COPD)
45
Norepinephrine, Epinephrine, Phenylephrine | Mechanism of Action, Therapeutic Use
1. a-1 agonist - increase BP through smooth muscle constriction 2. phenylephrine also decreases nasal congestion by constricting mucosal layers
46
Propanolol | Mechanism of Action, Therapeutic Uses, Metabolism
1. b-1 + b-2 competitive antagonist of norepinephrine 2. anti-arrhythmia, anti-HT, anti-HF 3. metabolized by CYP3A4

Foundations 2 (12 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions